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Gender Differences in Outcomes
of Patients with Cystic Fibrosis
Cayce L. Harness-Brumley, MD,1 Alan C. Elliott, MAS, MBA,2 Daniel B. Rosenbluth, MD,3
Deepa Raghavan, MD,1 and Raksha Jain, MD, MSCI1

Abstract

Background: Cystic fibrosis (CF) is a common life-shortening genetic disease in which women have been
described to have worse outcomes than males, particularly in response to respiratory infections with Pseudomonas aeruginosa. However, as advancements in therapies have improved life expectancy, this gender disparity
has been challenged. The objective of this study is to examine whether a gender-based survival difference still
exists in this population and determine the impact of common CF respiratory infections on outcomes in males
versus females with CF.
Methods: We conducted a retrospective cohort analysis of 32,766 patients from the United States Cystic
Fibrosis Foundation Patient Registry over a 13-year period. Kaplan-Meier and Cox proportional hazards models
were used to compare overall mortality and pathogen based survival rates in males and females.
Results: Females demonstrated a decreased median life expectancy (36.0 years; 95% confidence interval [CI]
35.0–37.3) compared with men (38.7 years; 95% CI 37.8–39.6; p < 0.001). Female gender proved to be a
significant risk factor for death (hazard ratio 2.22, 95% CI 1.79–2.77), despite accounting for variables known
to influence CF mortality. Women were also found to become colonized earlier with several bacteria and to
have worse outcomes with common CF pathogens.
Conclusions: CF women continue to have a shortened life expectancy relative to men despite accounting for
key CF-related comorbidities. Women also become colonized with certain common CF pathogens earlier than
men and show a decreased life expectancy in the setting of respiratory infections. Explanations for this gender
disparity are only beginning to be unraveled and further investigation into mechanisms is needed to help
develop therapies that may narrow this gender gap.

Introduction

C

ystic fibrosis (CF) is one of the most common genetic,
fatal diseases in the United States. It is a multisystem
disorder that is characterized by nutritional deficiency and
recurrent respiratory infections due to thick mucus, caused by
lack of chloride transport across surface epithelium. Advancements in therapies have improved the median life expectancy from less than 5 years of age in the 1950s to nearly
40 years of age currently.1 These advancements began with
the advent of pancreatic enzyme supplementation in the
1940s to help with malnutrition and progressed to therapies
aimed at thinning airway mucus and fighting lung infections
such as dornase alpha and nebulized Tobramycin respectively in the 1990s.2,3 Most recently ivacaftor, a therapy that
1
2
3

works to correct the underlying chloride channel protein
defect, was approved for patients with certain genetic mutations.4 However, despite these improvements in treatment,
females with CF have worse outcomes than males for reasons
that are only beginning to be understood.5 Chronic respiratory infections remain the largest contributor to morbidity
and mortality in CF patients, and we therefore hypothesized
that females have more severe responses to respiratory infections then males, contributing to their poorer outcomes.
A variety of respiratory diseases show a gender disparity in
prevalence and/or outcomes. For example, lymphangioleiomyomatosis is a rare cystic lung disease of unknown etiology
well known to disproportionately affect young women of
childbearing age.6 In fact, very few men have ever been reported to have this disease. This disease was hypothesized to
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be hormone mediated, but hormone based therapies have not
proven to be clearly beneficial as of yet.6 Observational data
suggest other diseases such as idiopathic pulmonary hypertension are more prevalent in women, whereas idiopathic
pulmonary fibrosis, disproportionately affects men.7–9 Further, in relationship to malignancies in the lung, malignant
mesothelioma disproportionately affects men, whereas women are more likely to have adenocarcinoma, yet men have
worse outcomes when affected by adenocarcinoma.10–12
Multiple epidemiologic studies have established that women
have worse outcomes than men in several airway diseases
beyond CF, such as asthma and chronic obstructive pulmonary disease (COPD).5,13–16 Post-puberty, girls with asthma
have more frequent and severe exacerbations than boys.17 In
COPD, women develop evidence of airway obstruction after
fewer numbers of cigarettes per lifetime than men, and
women with severe COPD have a 50% increased risk of death
compared to men.16 In non-CF bronchiectasis, females have
been shown to have a higher prevalence of the disease than
males, particularly in conjunction with nontuberculous mycobacterial infections, despite no known difference in immunologic susceptibility.13
Reports that women with CF have lower survival rates than
men first appeared in the 1990s.18–20 Rosenfeld and colleagues published a large cohort analysis using data from the
United States Cystic Fibrosis Foundation Patient Registry
(CFFPR) between 1988 through 1992, showing that women
had shorter life expectancies than men.5 This difference was
significant even after adjusting for confounding morphometric and nutritional factors. Another group demonstrated
that CF females acquired chronic Pseudomonas aeruginosa
infection, one of the most prevalent and virulent bacteria in
this population, at an earlier age (median of 9.5 years in
females and 11.2 years in males) and had a more rapid decline
in lung function after P. aeruginosa colonization.21 Since that
time, several reports have refuted the gender gap observation
in CF, arguing that improved airway clearance therapies have
narrowed the gender difference.22–25
Despite the controversy, multiple reports have evaluated
mechanisms behind the gender disparity in CF and focused
on the role of female sex hormones. In particular, estrogen
has been implicated as a hormone that decreases air surface
liquid on bronchial epithelial cells by modulating ion channels on airway epithelium and therefore renders CF females
at a greater disadvantage than males by enhancing mucus
viscosity. In addition, estrogen has been shown to promote
conversion of P. aeruginosa from a nonmucoid to mucoid
form in CF, which is the more drug resistant and pathogenic
form.22–25 Increasing evidence is demonstrating that pathogens beyond P. aeruginosa are important variables in survival of patients with CF, including methicillin resistant
Staphylococcus aureus (MRSA).26
We, therefore, sought to utilize the United States CFFPR to
determine if a survival difference remains in men and women
with CF and evaluate the effect of respiratory infections on
outcomes between males and females with CF.
Methods
Participants

The CF Foundation Patient Registry contains demographic
and clinical data collected at United States centers accredited
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by the CF Foundation and captures 92% to 97% of CF deaths
reported in the U.S.20 The United States CFFPR has evolved
to allow the examination of more and more CF pathogens to
be feasible. Reported microbiology data in the CFFPR
changed in 1994 to include a much more detailed profile than
in the past. From 1994 to 1997, positive cultures were reported annually.26 Cultures were reported quarterly from
1998 through 2002, and at each encounter since 2003. Due to
these changes in collection, we utilized only data from the
annual data set to stay consistent over the time course of
analysis. Positive culture data were defined as greater than or
equal to two positive cultures across annual data sets for all
bacteria included other than Burkholderia cepacia, which
was defined as present if ever positive. Subjects for this study
were CF patients with data entered from CFF-accredited care
centers between January 1, 1995 and December 31, 2007.
Design and statistical analysis

Differences in demographic variables were determined
using chi-squared tests for categorical variables and t-tests for
continuous variables. We performed a survival analysis using
Kaplan-Meier methodology. Age at entry into the cohort was
defined as age of diagnosis. The primary outcome was the
time from age at entry into the cohort until age at death from
any cause, as reported in previous CF literature.26 The CFF
registry captures 90 percent of patient deaths. Therefore, at
the end of the study period, subjects were either categorized
as dead or assumed to be alive, and censored at their age on
December 31, 2007. Patients who underwent lung transplantation were excluded. A log-rank analysis was used to
determine statistical differences in survival times between
men and women.
Cox proportional hazards models were used to analyze the
effects of multiple variables on mortality. Time independent
variables included were gender, race, CF genotype, date of
birth (cohorts were grouped by increments of 10 years), cause
of death, highest recorded sweat chloride value, pancreatic
functional status (defined as whether or not the subject was
using enzyme replacements), and presence or absence CFrelated diabetes (CFRD). Diabetes was defined as whether or
not the subject was listed as having CFRD or having a hemoglobin A1c greater than 6.1.27 Positive culture data were
defined as greater than or equal to two positive cultures across
annual data sets for all bacteria included other than B. cepacia,
which was defined as present if ever positive. Burkholderia
species information in the CFFPR does not differentiate mucoid from nonmucoid strains.
Time-dependent variables analyzed in the Cox proportional hazard model were height and body mass index (BMI)
(z-scores), percent of forced expiratory volume in 1 second
(%FEV1), and rate of pulmonary exacerbations. Pulmonary
exacerbations were defined as use of intravenous antibiotics
for the purpose of treating a CF exacerbation. The effect of
continuous variables on mortality rates was further analyzed
using a lag-two method in order to account for possible differences that may be due to imbalances in severity of illness
or aggressive treatment in the last years of life. In other
words, for time-dependent covariates, the covariate values at
age t-2 were used as predictors. Similar results were noted
using both methods of analysis and no interactions were
found between variables in the model. Individual pathogen
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influence on gender-based survival was analyzed using a
multivariate Cox proportional hazard analysis with gender as
a time independent variable and pathogen as a time-dependent
variable.
Age of pathogen acquisition as a mean with standard deviations and life expectancy after infection as a median with
confidence intervals were evaluated using independent twotailed t-tests. All data was analyzed using SAS software,
version 9.3 (SAS Institute). This study was approved by the
University of Texas Southwestern Medical Center Institutional Review Board and was waived of informed consent
given subjects had previously agreed to participation in the
CFF registry.
Results
Cohort characteristics

This study is a retrospective cohort analysis of 34,693
patients in the CFFPR (Fig. 1). Patients who received an
organ transplant (1,857) were excluded given that their survival would be altered by organ transplantation, leaving
32,836 subjects. A group of 70 subjects were found to have a
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negative value for survival, likely due to data entry error and
were also excluded. Therefore, a total of 32,766 subjects were
included in the final analysis with 17,174 males and 15,592
females, of which 12.6% of males died and 14.3% of females
died (Fig. 1).
Comparisons of important CF demographic and clinical
characteristics between men and women in this cohort are
shown in Table 1. Distribution of race and genotypes in males
and females were similar though females had lower sweat
tests. Date of birth cohort and lung function as measured by
%FEV1 were statistically different between groups but
without extreme imbalances in subgroups. The percentage of
men with pancreatic insufficiency was higher, while the
highest risk for an abnormal BMI was in females. CF-related
diabetes was more prevalent in females. Presence of mucoid
and nonmucoid P. aeruginosa, MRSA, and Achromobacter
xylosoxidans was higher in females, while presence of
B. cepacia was higher in males. Finally, more females died
of respiratory and cardio-respiratory causes than males and
females had on average an increased number of acute exacerbations per year than males.
Survival analysis

FIG. 1. Diagram of the study population of cystic fibrosis
patients from the Cystic Fibrosis Foundation Patient Registry analyzed by gender. A total of 34,693 subjects were
evaluated for this analysis. Subjects who received a lung
transplant were excluded, resulting in 32,836 subjects. There
were 70 patients whose survival lengths (SURV) were found
to be less than zero and were therefore not included. There
remained 32,766 subjects, of whom 17,174 were men and
15,592 were women.

Kaplan-Meier analysis demonstrated a significant difference in survival of CF males versus females ( p < 0.001) with
a median life expectancy of 38.7 years (95% confidence interval [95% CI] 37.8–39.6) in males and 36.0 years (95% CI
35.0 37.3) in females (Fig. 2). Risk of death was analyzed
using Cox proportional analysis with all variables included in
this study (Table 2). Importantly, females were more likely to
die than males (hazard ratio [HR] 1.252, 95% CI 1.180–
1.328, p < 0.001). Variables that have been previously described to impact survival in CF were similarly found to be
significant risk factors for death in our study, including BMI,
pancreatic insufficiency, %FEV1, CF-related diabetes, and
colonization with P. aeruginosa, MRSA, and B. cepacia.18,19,28,29 Other pathogens found to be associated with
increased risk of death included Klebsiella pneumoniae, Escherichia coli, A. xylosoxidans, other gram negative organisms, and Aspergillus species, but not methicillin-sensitive
Staphylococcus aureus (MSSA) or Haemophilus infuenzae.
Mortality also increased with increasing number of pulmonary exacerbations as described previously (1.7 in males and
2.2 in females, p < 0.001).30
In order to account for the influence of other variables on
gender-related outcomes, all variables from the univariate
analysis were included in a multivariate model (Table 3).
There remained an increased risk of death associated with
female gender (adjusted HR 2.227, 95% CI 1.790–2.771,
p < 0.0001). Other variables in the model associated with
increased risk of death when accounting for all other variables
included number of pulmonary exacerbations, pancreatic insufficiency, CF-related diabetes, mucoid and nonmucoid
P. aeruginosa, MRSA, and B. cepacia, as previously reported.18,19,29 Date of birth cohorts were included in the
multivariate model, but did not reveal statistical significance
and are therefore not displayed on Table 3.
Gender differences in age of infection and outcomes

We further evaluated gender-based differences in microbial infection. We assessed mean age of first pathogen
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Table 1. Demographic Characteristics of Male and Female Cystic Fibrosis Patients
Seen at Cystic Fibrosis Foundation-Accredited U.S. Care Centers

Racea
White
Hispanic
African American
Sweat chloride, mean – SD
CFTR genotype,a n (%)
F508del/F508del
F508del/Other
Other/Other
Date of birth cohort,a n (%)
1958–1967
1968–1977
1978–1987
1988–1997
1998–2007
BMI risk,a,b n (%)
Low ( ‡ 22)
Mild (20–21.9)
Moderate (18–19.9)
High ( < 18)
Height (percent),b mean – SD
FEV1,a,b % predicted, n (%)
> 80
60–79
40–59
< 40
Number of pulmonary exacerbations per year, mean – SD
Pancreatic insufficiency, n (%)
CF-related diabetes, n (%)
Pseudomonas aeruginosa, nonmucoid, n (%)
P. aeruginosa, mucoid, n (%)
MSSA, n (%)
MRSA, n (%)
Haemophilus influenzae, n (%)
Klebsiella pneumonia, n (%)
Escherichia coli, n (%)
Achromobacter xylosoxidans, n (%)
Other gram negatives, n (%)
Burkholderia cepacia, n (%)
Aspergillus species, n (%)
Nontuberculous mycobacterium, n (%)
Cause of death,a n (%)
Cardiopulmonary
Liver disease
Trauma
Suicide
Other
Unknown

Male
n = 17,174
(52.4%)

Female
n = 15,592
(47.6%)

14,974 (87.2%)
1,316 (7.6%)
734 (4.3%)
99.1 – 20.8
n = 14,701

13,653 (87.6%)
1,145 (7.3%)
639 (4.1%)
98.3 – 21.0
n = 13,192

6,853 (39.9%)
5,302 (30.9%)
2,066 (12.0%)

6,311 (40.5%)
5,043 (32.3%)
1,821 (11.7%)

3,734
5,089
4,557
2,509
1,285

3,687
4,643
4,040
2,098
1,116

p value
0.373

< 0.001
0.116

0.0001
(21.7%)
(29.6%)
(26.5%)
(14.6%)
(7.5%)

(23.6%)
(29.8%)
(25.9%)
(13.5%)
(7.2%)
< 0.001

2,265 (13.2%)
3,076 (17.9%)
2,867 (16.7)
8,966 (52.2%)
33.6 – 27.3%
n = 15,077

1,514 (9.7%)
2,919 (18.7%)
2,728 (17.5%)
8,431 (54.1%)
34.9 – 27.3%
n = 13,711

5,645 (32.9%)
2,690 (15.7%)
2,114 (12.3%)
6,725 (39.1%)
1.7 – 3.1
n = 16,175
14,960 (87.1%)
2,214 (12.9%)
10,762 (62.7%)
8,442 (49.2%)
14,521 (84.6%)
4,277 (24.9%)
9,902 (57.7%)
2,057(12.0%)
2,361 (13.8%)
5,070 (29.5%)
7,815 (45.5%)
1,494 (8.7%)
5,783 (33.7%)
921 (5.4%)

4,746 (30.4%)
2,475 (15.9%)
2,255 (14.5%)
6,116 (39.2%)
2.2 – 3.4
n = 14,667
13,093 (84.0)
2,499 (16.0%)
10,222 (65.6%)
7,933 (50.9%)
13,137 (84.3%)
4,087 (26.2%)
8,892 (57.0%)
1,965 (12.6%)
2,329 (15.0%)
5,152 (33.0%)
7,198 (46.2%)
1,221 (7.8%)
5,345 (34.3%)
893 (5.4%)

< 0.001
< 0.001

1,823
63
60
12
135
79

(83.9%)
(2.9%)
(2.8%)
(0.6%)
(6.2%)
(3.6%)

1,975
40
18
1
127
77

< 0.001
< 0.0001
< 0.001
< 0.0001
0.002
0.456
0.007
0.251
0.085
0.002
< 0.0001
0.231
0.004
0.246
0.942
< 0.001

(88.2%)
(1.8%)
(0.8%)
(0.1%)
(5.7%)
(3.4%)

a
Using a Bonferroni adjustment for multiple tests, a p value of < 0.002 should be considered statistically significant. This adjustment
controls the overall table error rate for the table at 0.05.
b
Variables analyzed as lag 2 (2 years prior to death) for demographics.
BMI, body mass index; CFTR, cystic fibrosis transmembrane conductance regulator; F508del, deltaF508 gene mutation; FEV1, forced
expiratory volume in 1 second; MRSA, methicillin resistant staphylococcus aureus; MSSA, methicillin sensitive staphylococcus aureus;
SD, standard deviation
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Table 2. Univariate Cox Regression for Survival
Variables

FIG. 2. Kaplan Meier estimate of survival comparing
cystic fibrosis (CF) women with men seen at accredited U.S.
CF care centers from 1995 to 2007. Females had poorer
survival, with a median life expectancy of 36.0 years (95%
CI 35.0–37.3) versus 38.7 years (95% CI 37.8–39.6) in men
( p < 0.001).
acquisition and impact of infection on survival outcomes in
males versus females (Table 4). Females acquired nonmucoid and mucoid P. aeruginosa, MSSA, MRSA, H. influenza, A. xylosoxidans, other gram negative organisms,
Aspergillus species, and nontuberculous mycobacterium at
significantly earlier ages than males, with the largest age
difference being in those with atypical mycobacterium.
Moreover, we evaluated gender specific mortality in males
versus females infected with these pathogens and found females to have a decreased life expectancy with all pathogens except K. pneumonia. Importantly, bacteria previously
reported to impact survival in CF such as P. aeruginosa,
MRSA, and B. cepacia were associated with poorer survival
outcomes in females.18,19,26 In addition, pathogens in a variety of categories including nontuberculous mycobacterium,
fungi and bacteria showed disparities.
Finally, we examined the individual effects of pathogens on
female gender-based survival using multivariate analysis (Table
5). All pathogens increased female-based risk of death from the
original hazard ratio of 1.252. Interestingly, MRSA had a similar impact on female risk of death as mucoid and nonmucoid P.
aeruginosa, implying that these gender-based mechanisms may
not be unique to gram negative bacteria or to P. aeruginosa.
Discussion

This large registry analysis demonstrated that women with
CF have worse outcomes than men, are predisposed to earlier
respiratory infections and have decrease life expectancies
once colonized with respiratory pathogens. We examined
32,766 CF patients in the United States, and show for the first
time that there are gender-based differences in microbial
infection in CF airways beyond P. aeruginosa.
Previous groups have demonstrated worse outcomes in CF
women relative to men, particularly in the 1990s.5,18,19 Since
that time, a host of literature has supported or refuted this
gender disparity. The potential explanations for a genderbased difference in CF patients are only beginning to be revealed. Some of the hypotheses for the worse outcomes in
women with CF have included descriptions of an immuno-

Female
Racea
White
Hispanic
African American
Sweat Chloride
CFTR genotypea
F508del/F508del
F508del/other
Other/other
Date of birth cohorta
1958–1967
1968–1977
1978–1987
1988–1997
1998–2007
BMI (z-score)b
Height (z-score)b
FEV1, % predicted
Number of pulmonary
exacerbations per year,
mean
Pancreatic insufficiency
CF-related diabetes
Pseudomonas aeruginosa,
nonmucoid
P. aeruginosa, mucoid
MSSA
MRSA
Haemophilus influenzae
Klebsiella pneumonia
Escherichia coli
Alcaligenes xylosoxidans
Achromobacter
xylosoxidans
Other gram negatives
Burkholderia cepacia
Aspergillus species
Nontuberculous
mycobacteria

Hazard ratio
(95% CI)

p value

1.252 (1.180–1.328)

< 0.0001

0.771
1.937
1.191
1.001

(0.661–0.887)
(1.720–2.181)
(1.018–1.394)
(0.999–1.003)

0.0003
< 0.0001
0.0295
0.2732

1.068 (0.992–1.150)
0.895 (0.828–0.967)
1.107 (0.982–1.248)

0.0956
0.0049
0.0824

(0.468–0.560)
(0.950–1.083)
(1.321–1.512)
(1.072–1.328)
(1.309–2.124)
(0.231–.0261)
(0.676–0.697)
(0.944–0.951)
(1.137–1.146)

< 0.0001
0.6695
< 0.0001
0.0013
< 0.0001
< 0.0001
< 0.0001
< 0.0001
< 0.001

1.403 (1.062–1.854)
2.509 (2.035–3.092)
1.360 (1.169–1.583)

0.0173
< 0.0001
< 0.0001

2.183
0.714
2.371
0.562
2.197
2.150
2.765
1.780

(1.835–2.598)
(0.627–0.813)
(1.999–2.811)
(0.446–0.708)
(1.498–3.221)
(1.514–3.054)
(2.246–3.404)
(1.473–2.152)

< 0.0001
< 0.0001
< 0.0001
< 0.0001
0.0003
0.0001
< 0.0001
< 0.0001

1.641
2.615
1.665
1.283

(1.372–1.963)
(2.104–3.251)
(1.407–1.971)
(0.769–2.139)

< 0.0001
< 0.0001
< 0.0001
0.3390

0.512
1.014
1.414
1.193
1.668
0.245
0.687
0.947
1.141

a
Using a Bonferroni adjustment for multiple testing, a p value
of < 0.0016 should be considered statistically significant. This
adjustment controls the overall table error rate for the table at 0.05.
b
BMI and height calculated as z-scores using infant National Center
for Health Statistics (NHS) and Centers for Disease Control and
Prevention (CDC) tables.22
95% CI, 95% confidence interval; CFTR, cystic fibrosis transmembrane conductance regulator.

logic difference resulting in earlier infections and poorer
responses to organisms such as P. aeruginosa.21,31,32 Chotirmall and colleagues demonstrated that estrogen induces
mucoid conversion of P. aeruginosa, a more antibiotic
resistant form of the bacteria, and showed an association
between increased exacerbations and mucoid conversion in
women with CF during high estrogen states.31 We found that
not only do women acquire P. aeruginosa at an earlier
age, but they also acquire MSSA, MRSA, H. influenzae,
A. xylosoxidans, B. cepacia, Aspergillus species, and nontuberculous mycobacterium at earlier ages, often even prior
to puberty. This earlier acquisition was combined with
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Table 3. Multivariate Cox Regression
for Survival
Relative hazard
ratio (95% CI)

Variables adjusted for
Female
White race
Hispanic race
African American race
F508del/F508del
F508del/other
BMIa (z-score)
Heighta (z-score)
FEV1, % predicted
Number of pulmonary
exacerbations per year
Pancreatic insufficiency
CF-related diabetes
Pseudomonas aeruginosa,
nonmucoid
P. aeruginosa, mucoid
MSSA
MRSA
Haemophilus influenzae
Klebsiella pneumoniae
Escherichia coli
Achromobacter
xylosoxidans
Other gram negatives
Burkholderia cepacia
Aspergillus species
Nontuberculous
mycobacteria

2.227
0.457
1.723
0.443
0.749
0.913
0.348
0.609
0.955
1.088

p value

(1.790–2.771)
(0.256–0.815)
(1.284–2.313)
(0.215–0.912)
(0.548–1.023)
(0.667–1.250)
(0.264–0.459)
(0.564–0.657)
(0.949–0.960)
(1.069–1.107)

< 0.0001
0.008
0.0003
0.027
0.069
0.571
< 0.0001
< 0.0001
< 0.0001
< 0.0001

7.914 (2.871–21.814) < 0.0001
1.533 (1.164–2.018)
0.002
1.190 (0.971–1.458)
0.094
1.413
0.896
1.544
0.636
2.104
1.227
1.181

(1.175–1.775)
(0.732–1.097)
(1.222–1.952)
(0.412–0.981)
(1.113–3.975)
(0.648–2.325)
(0.881–1.584)

0.003
0.288
0.0003
0.041
0.022
0.530
0.265

1.264
1.638
1.250
1.230

(0.957–1.670)
(1.120–2.397)
(0.999–1.563)
(0.671–2.254)

0.099
0.011
0.051
0.504

a

BMI and height calculated as z-scores using infant NHS and
CDC tables.30 [30]

increased mortality in women versus men in those with
mucoid and nonmucoid P. aeruginosa, MRSA, A. xylosoxidans, B. cepacia, Aspergillus species, and nontuberculous
mycobacterium among others. Therefore the sensitivity of
women to infections in CF is not unique to P. aeruginosa and
spans other gram negative organisms, gram positive organisms, nontuberculous mycobacterium, and fungal infections.
Descriptions of a gender disparity in nontuberculous mycobacterial infections outside of CF have been well described
where women are at increased risk for infection, but primarily
later in life, particularly after menopause.33–35 A genetic
basis may underlie this as at least one study found that 36%
of patients with mycobacterial infection who did not have
CF did carry one cystic fibrosis transmembrane conductance
regulator (CFTR) disease-causing gene, while others have
hypothesized morphometric or nutritional explanations.33–35
Though the cause of the gender disparity in infectious susceptibility is unclear, preventing early acquisition of infections serves as a potential avenue of future studies and
treatments.
Several groups have also reported that sex hormones alter components of the mucociliary apparatus, comprised of
mucus, cilia, and the airway epithelial air surface liquid layer.
The mucociliary apparatus serves as a unique mechanism by
which the airways protect the lungs from infection by trapping pathogens and propelling them out of the lungs. Reports
demonstrated that sex hormones impact airway epithelial
cell apical sodium and chloride transport,36,37 alter airway
surface liquid (ASL) volume,38 influence inflammatory mediators that can predispose to infection and colonization,31
and change cilia beat frequency in the airways.39 It is still
unknown if these effects directly translate to poorer female
outcomes; however, estrogen was shown to decrease chloride

Table 4. Pathogen Acquisition and Life Expectancy in CF Males Versus Females

Variable

Sex

Number
of subjects

Pseudomonas aeruginosa, nonmucoid

M
F
M
F
M
F
M
F
M
F
M
F
M
F
M
F
M
F
M
F
M
F
M
F

10,762
10,222
8,442
7,933
14,521
13,137
4,277
4,087
9,902
8,892
2,057
1,965
2,070
1,965
5,070
5,152
7,815
7,198
1,494
1,221
5,783
5,345
921
839

P. aeruginosa, mucoid
MSSA
MRSA
Haemophilus influenzae
Klebsiella pneumoniae
Escherichia coli
Achromobacter xylosoxidans
Gram negatives
Burkholderia cepacia
Aspergillus species
Nontuberculous mycobacteria

Mean age of
first culture
(years) – SD

p value
(time to first
culture)

10.87 – 9.44
10.03 – 9.12
13.32 – 8.99
12.46 – 8.80
5.68 – 7.65
5.37 – 7.38
12.40 – 9.33
11.72 – 9.12
6.16 – 7.52
5.91 – 7.44
4.42 – 8.36
4.70 – 8.50
4.96 – 8.87
4.78 – 8.52
10.47 – 9.02
10.01 – 8.83
8.71 – 9.43
8.33 – 9.20
13.71 – 8.41
13.16 – 8.36
13.13 – 8.69
12.54 – 8.48
16.27 – 9.56
14.73 – 9.24

< 0.0001
< 0.0001
0.0008
0.0007
0.0208
0.2930
0.5230
0.0104
0.0130
0.0930
0.0003
0.0006

Median age
of death (years)
(95%CI)
41.7
39.5
41.5
38.9
39.8
37.6
41.5
40.7
39.9
39.0
40.0
40.3
41.1
38.9
40.3
38.5
39.8
38.5
32.3
29.1
41.5
37.2
46.4
44.6

(40.5–43.6)
(38.2–40.9)
(39.6–43.5)
(38.0–40.7)
(38.8–41.7)
(36.1–38.6)
(38.8–45.9)
(38.6–44.6)
(38.8–42.2)
(37.8–40.9)
(36.0–45.1)
(35.0–45.2)
(36.8–45.9)
(33.7–43.6)
(38.8–43.7)
(36.5–40.1)
(38.5–41.0)
(36.6–39.7)
(31.3–33.7)
(28.0–30.4)
(39.4–43.0)
(35.4–38.6)
(44.2–49.7)
(39.0–49.1)

p value
(survival)
< 0.0001
< 0.0001
< 0.0001
0.0003
< 0.0001
0.0215
0.0013
< 0.0001
< 0.0001
0.0008
< 0.0001
0.0039
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Table 5. Multivariate Cox Regression
for Survival
Variables
Female
Pseudomonas aeruginosa,
nonmucoid
Female
P. aeruginosa, mucoid
Female
MSSA
Female
MRSA
Female
Haemophilus influenzae
Female
Klebsiella pneumonia
Female
Escherichia coli
Female
Achromobacter
xylosoxidans
Female
Other gram negatives
Female
Burkholderia cepacia
Female
Aspergillus species
Female
Nontuberculous
mycobacteria

Hazard ratio
(95% CI)

p value

1.598 (1.384–1.844)
1.346 (1.156–1.566)

< 0.0001
0.0001

1.606
2.179
1.508
0.723
1.593
2.348
1.518
0.562
1.520
2.183
1.523
2.171
1.511
1.756

(1.392–1.854)
(1.832–2.592)
(1.330–1.709)
(0.635–0.823)
(1.399–1.813)
(1.980–2.784)
(1.339–1.720)
(0.448–0.711)
(1.340–1.723)
(1.489–3.199)
(1.344–1.727)
(1.528–3.083)
(1.333–1.713)
(1.453–2.123)

< 0.0001
< 0.0001
< 0.0001
< 0.0001
< 0.0001
< 0.0001
< 0.0001
< 0.0001
< 0.0001
< 0.0001
< 0.0001
< 0.0001
< 0.0001
< 0.0001

1.519
1.637
1.533
2.656
1.516
1.655
1.521
1.279

(1.340–1.722)
(1.369–1.958)
(1.352–1.738)
(2.137–3.302)
(1.337–1.718)
(1.398–1.959)
(1.342–1.724)
(0.767–2.133)

< 0.0001
< 0.0001
< 0.0001
< 0.0001
< 0.0001
< 0.0001
< 0.0001
0.3452

secretion via calcium mediated chloride channels in women
with CF as measured by changes in nasal potential difference,
and resulted in decreased airway surface liquid volume in CF
airway epithelium.38 This altered mucociliary clearance apparatus may explain in part the disadvantage females have to
an array of pathogens in CF. Respiratory infections typically
trigger CF exacerbations in these patients and our group also
demonstrated that post-puberty CF women have a distinct
increase in rate of pulmonary exacerbations relative to men.40
However, sex hormones are likely not the only explanation
for this gender disparity given that some reports suggest the
gender difference in CF may start before pubertal hormone
surges and that we demonstrated earlier bacterial infection in
females in this study prior to puberty in several cases.5
Other evidence hypothesizes possible differences in innate
immune response. One report showed that estrogen inhibited
interleukin-8 production in CF bronchial epithelial cells
in vitro and hypothesized that this would hinder neutrophil
recruitment and inflammatory responses in women.41–43 Others
have shown that estrogen inhibits the respiratory burst in
neutrophils, potentially hindering their killing capacity. Others
believe that the gender disparity has very little to do with host
immunity and more to do with gender-based differences in
morphometrics, such as airway diameter or airway branch
angles, which has not yet been evaluated. This type of data was
not available in this study given the lack of radiology imaging
in association with this database, but would be interesting to
explore at a more local CF center level.

Given that our study was retrospective in design, there are
several other inherent limitations to this study. For example,
variables not available in the registry that could impact results include patient exercise habits and adherence to medications. We also did not incorporate medications prescribed
in the analysis. Though we lacked these data, previous studies
showed no differences in adherence to therapies between
males and females with CF.44 Further, we were unable to
determine if earlier radiographic changes were seen in females versus males, as is often described to occur even prior
to changes in lung function or if bronchiectasis severity
scores were worse in women relative to men. These types of
analysis would be interesting to perform at single centers that
can perform radiographic correlates. In addition, details regarding pulmonary exacerbations such as which patients received antibiotics for a true exacerbation versus a ‘‘tune-up’’
or ‘‘clean-out’’ was also unavailable. The microbiology data
in this study suggests that women have a higher prevalence
and worse outcome once infected with several bacteria beyond P. aeruginosa, however, we submit that we excluded
transplant patients from this analysis, which could have impacted the results. Finally, we did not have data on socioeconomic status or environmental factors that could impact
male versus female outcomes and acknowledge that these
kinds of variables could affect the results. Despite these
limitations, this is the largest analysis to suggest that women
with CF have worse outcomes in the setting of infections
beyond P. aeruginosa. Further work into mechanisms behind
this including the impact of hormones on innate immunity is
warranted.
Finally, the gender disparity in CF is not unique to this
airway disease. A host of literature supports worse outcomes
in females with asthma and COPD. Interestingly, this disparity is opposite to that seen in the global United States
population where the life expectancy for females is 80.9
versus 76.3 in males as of 2010, a 4.6 year difference in favor
of women as opposed to the 2.7 year difference in favor of
men found in our analysis, demonstrating a theoretical 7.3
year disadvantage in women with CF relative to the general
population. Therefore, further research into the mechanisms
behind this disparity is warranted and may shed light into
potential therapeutic options such as hormone modulating
therapies that may be delivered directly to the airways.
Conclusions

In conclusion, in evaluating the impact of gender on outcomes in a large CF cohort, females were found to have an
increased mortality, more commonly acquire infections at an
earlier age than males, and have shorter life expectancies
in the setting of respiratory infections. These findings were
seen in association with a number of pathogens including
gram positive, gram negative, fungal, and nontubercuous
mycobacterial organisms. This study corroborates a host of
literature describing potential disadvantages of women in
relation to airway diseases and supports the need for further
work to understand mechanisms behind this gender disparity.
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